Published in Healthcare Mergers, Acquisitions and Ventures Week, February 26th, 2005
The additional capital will support the firm's overall growth. Williams Mullen served as legal counsel to the company for the offering.
One immediate use of the added funds is the expansion of the company's laboratory capability. Research space has been doubled and the program has been strengthened with the purchase of equipment to conduct nuclear magnetic resonance spectrometer studies.
"This funding will allow Adenosine Therapeutics to enhance our discovery capabilities...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.